AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1612948
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of two cycles of cisplatin, bleomycin, vindesine and mitomycin C (first trial, 100 patients)
Trial: 1612948
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of three cycles of cisplatin, 5‐fluorouracil by continuous infusion and vindesine (second trial, 108 patients)
Trial: 1612948
Drug: Both chemotherapy
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both chemotherapy regimens
Trial: 6704275
Drug: naloxone 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 1.2 mg i.v.
Trial: 6704275
Drug: saline 3
RxNorm normalized name: CVS Saline 3.0% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 3 ml (placebo)
Trial: 26790207
Drug: Heat-sensitive moxibustion
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-sensitive moxibustion added to FOLFOX chemotherapy regimen
Trial: 26790207
Drug: FOLFOX chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX chemotherapy regimen alone (Control)
Trial: 21506241
Drug: Peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa‐2a (135 μg/week for 4 weeks and then 180 μg/week for 44 weeks) plus ribavirin (initial dose of 400 mg/day escalated to 1200 mg/day)
Trial: 21506241
Drug: Observation (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (treatment initiated upon significant HCV recurrence)
Trial: 17252706
Drug: Generic glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic glimepiride tablets (6 mg)
Trial: 17252706
Drug: Innovator glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator glimepiride tablets (6 mg)
Trial: 11744338
Drug: ADN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADN plus glutamine 0.15 g x kg(‐1) x d(‐1)
Trial: 11744338
Drug: ADN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADN plus glutamine 0.30 g x kg(‐1) x d(‐1)
Trial: 8121965
Drug: Carbamazepine; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine; specific dosage and duration not mentioned.
Trial: 2547030
Drug: MACC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACC + W (methotrexate, doxorubicin, cyclophosphamide, and lomustine plus warfarin)
Trial: 30784097
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 to 150 mg BID
Trial: 28973174
Drug: Low-dose alteplase
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alteplase (0.6 mg/kg; 15% as bolus and 85% as infusion over 1 hour)
Trial: 28973174
Drug: Standard-dose alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose alteplase (0.9 mg/kg; 10% as bolus and 90% as infusion over 1 hour)
Trial: 26169991
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (15 mg/kg before tourniquet deflation)
Trial: 26169991
Drug: Intra-articular TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular TXA (2 g via drain after wound closure)
Trial: 23948786
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg twice per day)
Trial: 16894334
Drug: Escitalopram (ESCIT)
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram (ESCIT) 10-20 mg/day (flexible dose) or 10 mg/day (fixed dose for the first 4 weeks)
Trial: 16894334
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestogen therapy (ethinyl estradiol 5 microg/day plus norethindrone acetate 1 mg/day)
Trial: 16894334
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestogen therapy (EPT)
Trial: 3675696
Drug: Amoxicillin 1500
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1500 mg/d + Ambroxol 90 mg/d (n = 10)
Trial: 3675696
Drug: Amoxicillin 1500
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1500 mg/d (n = 13)
Trial: 29235242
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention for the basic aspects of the diagnosis and treatment of osteoporosis
Trial: 27432166
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g) with lifestyle recommendations
Trial: 20335626
Drug: 5-mg zinc
RxNorm normalized name: zinc sulfate 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg zinc supplement
Trial: 20335626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-phytate maize and zinc supplement
Trial: 11761012
Drug: No omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No omeprazole treatment
Trial: 9250109
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg beta-carotene/d for 4 years
Trial: 8214666
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg MCA
Trial: 8214666
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg MCA
Trial: 8214666
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg MCA
Trial: 8214666
Drug: DPD (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPD (0.01 and 0.02 mg/kg)
Trial: 25510857
Drug: L-dopa (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (50 mg levodopa and 12.5 mg carbidopa)
Trial: 19006463
Drug: Internet-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based therapy (IBT)
Trial: 17585666
Drug: Red-hot needle
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Red-hot needle therapy combined with blood-letting puncture and cupping
Trial: 17585666
Drug: Halometasone cream
RxNorm normalized name: halometasone
DrugBank: Halometasone (DB13728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halometasone cream (control)
Trial: 7809761
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (bed rest, information, analgesics)
Trial: 3056084
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg continuous infusion in 5% glucose over 10 h)
Trial: 31246283
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks until further progression)
Trial: 26468007
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus cisplatin (CC)
Trial: 16426274
Drug: Chronic daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic daily headache (CDH)
Trial: 16426274
Drug: Drug addicts
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR SUBSTANCE ADDICTION TREATMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug addicts (DA)
Trial: 15533865
Drug: Avasimibe 50
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe 50 mg QD
Trial: 15533865
Drug: Avasimibe 250
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe 250 mg QD
Trial: 14644397
Drug: Avasimibe 750
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe 750 mg QD
Trial: 11375853
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GA and intraoperative thoracic epidural analgesia (TEA)
Trial: 11375853
Drug: Multimodal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal approach (intraoperative GA and TEA, postoperative patient‐controlled TEA, early oral nutrition, enforced mobilization)
Trial: 9466279
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg p.o. twice a day followed by a 2-month taper)
Trial: 25855155
Drug: Ceralifimod 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralifimod 0.10 mg
Trial: 25855155
Drug: Ceralifimod (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralifimod (0.05 mg)
Trial: 30852478
Drug: Fingolimod (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (0.5 mg)
Trial: 12105160
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) 10 mg/24 hours
Trial: 12105160
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) with ascorbate (2.4 g/24 hours)
Trial: 10022633
Drug: Long-term NSAID
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term NSAID therapy (Group I)
Trial: 10022633
Drug: No NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No NSAID therapy (Group II)
Trial: 8815569
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) certoparin (3,000 IU) combined with dihydroergotamine (DHE) (0.5 mg) subcutaneously once daily
Trial: 8815569
Drug: Adjusted-dose unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose unfractionated heparin (UFH) subcutaneously every 8 hours
Trial: 6339343
Drug: Spironolactone and
RxNorm normalized name: Spironolactone and torsemide only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone and 500 mg Na p.d
Trial: 6339343
Drug: Spironolactone +
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone + furosemide or Moduretic and 500 mg Na p.d
Trial: 6339343
Drug: Concentrated ascites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ascites reinfusion and 500 mg Na p.d
Trial: 6339343
Drug: Unmodified ascites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified ascites reinfusion and 500 mg Na p.d
Trial: 6339343
Drug: Slow ascites
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow ascites drainage and 500 mg Na p.d
Trial: 31450257
Drug: Solution-Focused Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-Focused Group Counseling (SFGC) for 5 sessions of 75 minutes each
Trial: 31450257
Drug: Solution-Focused Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-Focused Group Counseling (SFGC)
Trial: 23704830
Drug: Danzhijiangtang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danzhijiangtang capsule (DJC)
Trial: 21422407
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Exemestane and Tamoxifen)
Trial: 17199134
Drug: Bicalutamide 80
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 80 mg + LHRH-A
Trial: 15003438
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g liquid paraffin per day)
Trial: 15003438
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) (2 g per day)
Trial: 11307178
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of antioxidants
Trial: 6704272
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine
Trial: 3986067
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (morphine i.v.)
Trial: 27090364
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.pt) extract
Trial: 22933427
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (E+P or E‐alone)
Trial: 14654605
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg of elemental zinc as zinc sulfate in vitamin B complex‐based syrup, 1 mL daily)
Trial: 14654605
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of vitamin‐based syrup)
Trial: 11304647
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intramuscular haloperidol
Trial: 1738183
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of isotretinoin daily
Trial: 22234716
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) users
Trial: 20031720
Drug: Small-molecule glycoprotein
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide)
Trial: 9398932
Drug: L-alpha-acetylmethadol (LAAM)
RxNorm normalized name: alpha-tocopherol, L-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alpha-acetylmethadol (LAAM)
Trial: 1287107
Drug: Desipramine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine, 50 mg by mouth
Trial: 1287107
Drug: Intravenous morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine, 0.033 mg/kg
Trial: 1287107
Drug: Intravenous morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine, 0.10 mg/kg
Trial: 3907989
Drug: Pirprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirprofen (400 mg twice daily)
Trial: 25012645
Drug: Passive physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive physical therapy (group B)
Trial: 25056569
Drug: Broad-spectrum micronutrient
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum micronutrient treatment
Trial: 18572041
Drug: TLC diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC diet with 0.5 cups of soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Trial: 11879257
Drug: Antacid (30-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (30-ml dose of magnesium hydroxide/aluminium hydroxide)
Trial: 10999119
Drug: TRH study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH study in Group 3 (18 patients) with baseline TSH 5 to 10 mu IU/ml and exaggerated TSH response to TRH
Trial: 6113074
Drug: Clobazam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (30 to 80 mg/day)
Trial: 6113074
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 to 40 mg/day)
Trial: 31102650
Drug: Buccal film
RxNorm normalized name: Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal film containing microdoses of midazolam (30 μg)
Trial: 31102650
Drug: Buccal solution
RxNorm normalized name: POLICRESULEN 720 mg in 1 mL BUCCAL SOLUTION [ALBOTHYL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal solution of midazolam
Trial: 26495770
Drug: Slow titration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow titration of sertraline
Trial: 26495770
Drug: Regular titration
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular titration of sertraline
Trial: 9279219
Drug: Nebulized glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glutathione (GSH) 600 mg with 4 ml of 0.9% sodium chloride
Trial: 9279219
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical saline solution)
Trial: 3268179
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/Kg)
Trial: 3268179
Drug: Meperidine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (1.5 mg/Kg)
Trial: 3268179
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of morphine and meperidine
Trial: 29482033
Drug: In-treatment cotinine
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment cotinine decreases
Trial: 11239659
Drug: Digoxin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (1 mg) injected intra-amniotically 24 hours before the procedure
Trial: 7845827
Drug: Digoxin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (1 mg)
Trial: 9663724
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 28 days plus clarithromycin 500 mg b.d. for 7 days (Group A)
Trial: 9663724
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 28 days plus clarithromycin 500 mg b.d. for 14 days (Group B)
Trial: 7819689
Drug: Steroids only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids only (14 patients, 63.6%)
Trial: 7819689
Drug: Steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids and high-dose gamma globulin (4 patients)
Trial: 7819689
Drug: Steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids and splenectomy (2 patients)
Trial: 7819689
Drug: Steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids and immunosuppressive therapy (2 patients)
Trial: 7819689
Drug: Initial prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial prednisone course (1-5 mg/kg/day)
Trial: 7819689
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (4 patients, 18.2%)
Trial: 4035228
Drug: Flunarizine 10
RxNorm normalized name: flunarizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 10 mg/day
Trial: 2978324
Drug: Pizotifen 1.5
RxNorm normalized name: Pizotifen 1.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen 1.5 mg/day
Trial: 8245085
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (n = 25)
Trial: 8245085
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n = 31)
Trial: 8245085
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for undisplaced fractures (n = 10)
Trial: 3545844
Drug: Amoxicillin twice
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin twice daily (60 mg/kg per day for 10 days)
Trial: 3545844
Drug: Amoxicillin thrice
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin thrice daily (60 mg/kg per day for 10 days)
Trial: 3545844
Drug: Amoxicillin twice
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin twice daily
Trial: 3545844
Drug: Amoxicillin thrice
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin thrice daily
Trial: 3545844
Drug: Amoxicillin twice
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin twice daily and thrice daily
Trial: 25441408
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg/day, increasing to 50 mg/day if minimal toxicity)
Trial: 25441408
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m2 loading dose, then 250 mg/m2/week)
Trial: 22507365
Drug: Interferential laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential laser therapy (n=100)
Trial: 22507365
Drug: Conventional laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laser therapy (n=100)
Trial: 17513190
Drug: Active gel
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gel (lidocaine 20 mg/g)
Trial: 7863833
Drug: Alendronate, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 20 mg/day for 6 months